You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 24 No. 2, February 1971 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (50)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Metachromatic Leukodystrophy (MLD)

IX. Qualitative and Quantitative Differences in Urinary Arylsulfatase A in Different Forms of MLD

David Stumpf; James Austin, MD

Arch Neurol. 1971;24(2):117-124.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

METACHROMATIC leukodystrophy (MLD) is characterized by deficient activity of sulfatase A (arylsulfatase A; cerebroside sulfatase) and by a corresponding accumulation of cerebroside sulfate. The disease begins at different ages and evolves at different tempos. Late infantile, juvenile, adult, and variant forms occur. Each form tends to have subtly different clinical, neuropathological and chemical findings. How is one to explain the variation within this model disease? Are there any principles which, by extension, might give us a better understanding of the pathogenesis of other diseases? To begin to answer these questions we have started to characterize the minute amounts of enzyme activity which still remain in MLD.

Three aspects of sulfatase A have been studied: (1) the amount of sulfatase A activity present; (2) the kinetic parameters of the enzyme; and (3) the effect on the enzyme activity of various compounds known to interact with enzyme proteins. The purposes of . . . [Full Text PDF of this Article]


Author Affiliations

Denver

From the Division of Neurology, University of Colorado Medical Center, Denver.


Footnotes

Accepted for publication Sept 9, 1970.

Reprint requests to Division of Neurology, University of Colorado Medical Center, 4200 E Ninth Ave, Denver 80220 (Dr. Austin).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1971 American Medical Association. All Rights Reserved.